🇺🇸 FDA
Pipeline program

MK-1045

1045-002

Phase 2 small_molecule active

Quick answer

MK-1045 for Acute Lymphoblastic Leukemia is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Acute Lymphoblastic Leukemia
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials